MX2024012195A - Formas amorfas y cristalinas de los antagonistas de mci-1 - Google Patents
Formas amorfas y cristalinas de los antagonistas de mci-1Info
- Publication number
- MX2024012195A MX2024012195A MX2024012195A MX2024012195A MX2024012195A MX 2024012195 A MX2024012195 A MX 2024012195A MX 2024012195 A MX2024012195 A MX 2024012195A MX 2024012195 A MX2024012195 A MX 2024012195A MX 2024012195 A MX2024012195 A MX 2024012195A
- Authority
- MX
- Mexico
- Prior art keywords
- amorphous
- antagorists
- mci
- crystalline
- crystalline forms
- Prior art date
Links
- JQNINBDKGLWYMU-GEAQBIRJSA-N CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 Chemical compound CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 JQNINBDKGLWYMU-GEAQBIRJSA-N 0.000 abstract 2
- 241000534944 Thia Species 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327656P | 2022-04-05 | 2022-04-05 | |
| PCT/US2023/017505 WO2023196361A1 (en) | 2022-04-05 | 2023-04-05 | Amorphous and crystalline forms of mci-1 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012195A true MX2024012195A (es) | 2024-11-08 |
Family
ID=86386948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012195A MX2024012195A (es) | 2022-04-05 | 2024-10-02 | Formas amorfas y cristalinas de los antagonistas de mci-1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240140966A1 (enExample) |
| EP (1) | EP4504738A1 (enExample) |
| JP (1) | JP2025511331A (enExample) |
| AU (1) | AU2023250874A1 (enExample) |
| CA (1) | CA3255077A1 (enExample) |
| MX (1) | MX2024012195A (enExample) |
| TW (1) | TW202404982A (enExample) |
| UY (1) | UY40218A (enExample) |
| WO (1) | WO2023196361A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4519271A1 (en) | 2022-05-04 | 2025-03-12 | Gilead Sciences, Inc. | Salts and polymorphs of certain mcl-1 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| KR20230113577A (ko) * | 2020-11-25 | 2023-07-31 | 암젠 인크 | 알데히드의 거울상이성질체 선택적 알케닐화 |
-
2023
- 2023-04-05 WO PCT/US2023/017505 patent/WO2023196361A1/en not_active Ceased
- 2023-04-05 AU AU2023250874A patent/AU2023250874A1/en active Pending
- 2023-04-05 EP EP23724439.7A patent/EP4504738A1/en active Pending
- 2023-04-05 JP JP2024558382A patent/JP2025511331A/ja active Pending
- 2023-04-05 CA CA3255077A patent/CA3255077A1/en active Pending
- 2023-04-05 US US18/296,211 patent/US20240140966A1/en active Pending
- 2023-04-06 TW TW112112761A patent/TW202404982A/zh unknown
- 2023-04-10 UY UY0001040218A patent/UY40218A/es unknown
-
2024
- 2024-10-02 MX MX2024012195A patent/MX2024012195A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240140966A1 (en) | 2024-05-02 |
| CA3255077A1 (en) | 2023-10-12 |
| TW202404982A (zh) | 2024-02-01 |
| WO2023196361A1 (en) | 2023-10-12 |
| EP4504738A1 (en) | 2025-02-12 |
| JP2025511331A (ja) | 2025-04-15 |
| AU2023250874A1 (en) | 2024-10-10 |
| UY40218A (es) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024012195A (es) | Formas amorfas y cristalinas de los antagonistas de mci-1 | |
| DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| CL2021002137A1 (es) | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. | |
| CO2024013985A2 (es) | Moduladores del transductor de señal y activador de la transcripción (stat) y usos de los mismos | |
| PE20240493A1 (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer | |
| MX2024008616A (es) | Moduladores stat y usos de los mismos | |
| CO2024012743A2 (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| CL2020002839A1 (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas. | |
| MX2024003721A (es) | Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| DOP2024000231A (es) | Compuestos y usos de estos | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| CO5200848A1 (es) | Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales | |
| UY39517A (es) | Inhibidores de la btk | |
| CO2024012423A2 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CY1109891T1 (el) | Παραγωγα ν-(αρυλαλκυλ)-1η-πυρρολοπυριδιν-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες | |
| CL2020002663A1 (es) | Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos | |
| MX2025004315A (es) | Formas salinas de degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) | |
| CL2020002157A1 (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| AR114239A1 (es) | Oxadiazoles | |
| MX2021000462A (es) | Derivados de pirrolo-[1,2-b]-piridazina. | |
| MXPA03011954A (es) | Nuevos derivados de acido sulfonico. | |
| PE20230323A1 (es) | Compuestos de azalactama como inhibidores de hpk1 | |
| UY40217A (es) | Formas de sal y solvatos de antagonistas de mci-1 | |
| AR040579A1 (es) | Derivados de fenilalanina enamida |